These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7844615)

  • 41. Severe myelotoxicity in a combination of gefitinib and vinorelbine.
    Yoshimura M; Nakamura S; Imamura F; Ueno K; Yamamoto S; Igarashi T
    Lung Cancer; 2004 Jul; 45(1):121-3. PubMed ID: 15196742
    [No Abstract]   [Full Text] [Related]  

  • 42. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
    Fumoleau P; Delgado FM; Delozier T; Monnier A; Gil Delgado MA; Kerbrat P; Garcia-Giralt E; Keiling R; Namer M; Closon MT
    J Clin Oncol; 1993 Jul; 11(7):1245-52. PubMed ID: 8315421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
    Coltman CA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report.
    Vokes EE; Rosenberg R; Jahanzeb M; Craig J; Gralla R; Belani C; Jones S; Bigley J; Hohneker J
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):35-8; discussion 38-41. PubMed ID: 7973767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myocardial infarction following vinblastine treatment.
    Lejonc JL; Vernant JP; Macquin J; Castaigne A
    Lancet; 1980 Sep; 2(8196):692. PubMed ID: 6106802
    [No Abstract]   [Full Text] [Related]  

  • 46. [Pharmacological elucidation and pharmaceutical intervention to reduce antitumor drug-induced vascular injury].
    Yano T; Yamada T; Oishi R
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):51. PubMed ID: 23842229
    [No Abstract]   [Full Text] [Related]  

  • 47. Cutaneous recall phenomenon with vinorelbine.
    Gómez-Ulloa D; Bundó AV; Antonio JM; Arriola E; Conde-Estévez D
    Ann Pharmacother; 2011 Sep; 45(9):1168-9. PubMed ID: 21862715
    [No Abstract]   [Full Text] [Related]  

  • 48. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
    Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two cases of chlorinated hydrocarbon-associated myocardial ischemia.
    Bailey B; Loebstein R; Lai C; McGuigan MA
    Vet Hum Toxicol; 1997 Oct; 39(5):298-301. PubMed ID: 9311088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
    Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
    Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.
    Chan A; Shannon C; de Boer R; Baron-Hay S; Redfern A; Bauwens A; Craft P; Webb S; Townsend A; Kotasek D
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):368-75. PubMed ID: 25351929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cardiac toxicity by carboplatin].
    Gómez M; Villuendas R; Serés L; Valle V
    Med Clin (Barc); 2003 Oct; 121(11):436. PubMed ID: 14563278
    [No Abstract]   [Full Text] [Related]  

  • 53. Vascular toxicity associated with antineoplastic agents.
    Doll DC; Yarbro JW
    Semin Oncol; 1992 Oct; 19(5):580-96. PubMed ID: 1411655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myocardial ischaemia, radiotherapy, and vinblastine.
    Harris AL; Wong C
    Lancet; 1981 Apr; 1(8223):787. PubMed ID: 6110992
    [No Abstract]   [Full Text] [Related]  

  • 55. [Research progress on detection of chemotherapy induced myocardial injury by cardiovascular magnetic respnance].
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):546-549. PubMed ID: 28648035
    [No Abstract]   [Full Text] [Related]  

  • 56. Vinblastine-induced erythrocytotoxicity.
    Neville AJ; Rand CA; Barr RD
    Scand J Haematol; 1982 Jan; 28(1):32-8. PubMed ID: 7071515
    [No Abstract]   [Full Text] [Related]  

  • 57. Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences.
    Lange SA; Reinecke H
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toward a broader view of mechanisms of drug cardiotoxicity.
    Mamoshina P; Rodriguez B; Bueno-Orovio A
    Cell Rep Med; 2021 Mar; 2(3):100216. PubMed ID: 33763655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Why aren't we getting consistent results for heart dose and mortality during thoracic radiotherapy?
    Xue J; Lu Y; Kong FS
    Ann Transl Med; 2020 Oct; 8(19):1252. PubMed ID: 33178784
    [No Abstract]   [Full Text] [Related]  

  • 60. Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer.
    Xue J; Han C; Jackson A; Hu C; Yao H; Wang W; Hayman J; Chen W; Jin J; Kalemkerian GP; Matuzsak M; Jolly S; Kong FS
    Radiother Oncol; 2019 Apr; 133():213-219. PubMed ID: 30416046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.